Diversified Healthcare Trust – (NASDAQ:DHCNI) Short Interest Down 65.9% in July

Diversified Healthcare Trust – (NASDAQ:DHCNI) was the recipient of a significant drop in short interest in July. As of July 15th, there was short interest totaling 18,696 shares, a drop of 65.9% from the June 30th total of 54,805 shares. Based on an average daily trading volume, of 14,429 shares, the short-interest ratio is currently 1.3 days.

Diversified Healthcare Trust Stock Up 0.9%

NASDAQ DHCNI traded up $0.16 during trading hours on Monday, hitting $18.12. 13,953 shares of the company’s stock traded hands, compared to its average volume of 62,773. Diversified Healthcare Trust has a 52-week low of $15.61 and a 52-week high of $19.09. The firm’s 50-day moving average is $18.24 and its 200-day moving average is $17.74.

Diversified Healthcare Trust Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Saturday, August 1st. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.3516 per share. This represents a $1.41 annualized dividend and a dividend yield of 7.8%. The ex-dividend date is Wednesday, July 15th.

Diversified Healthcare Trust (NASDAQ: DHCNI) is a publicly traded real estate investment trust (REIT) specializing in healthcare and life science properties. The company’s primary business activities include the acquisition, development, ownership and management of net‐leased medical office buildings, senior housing facilities and life science research and development assets. In addition to property investments, Diversified Healthcare Trust holds mortgage loans and preferred equity interests in the healthcare sector, offering diversified exposure to both real estate and structured financing arrangements.

The company’s portfolio spans a broad range of healthcare asset types, including medical office buildings leased to health systems and physician groups, senior living communities operated by leading care providers, and life science campuses serving biotechnology and pharmaceutical companies.